| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.22805 |
| P698 | PubMed publication ID | 17665424 |
| P2093 | author name string | van der Heijde D | |
| Zhou B | |||
| Gladman DD | |||
| Krueger GG | |||
| de Vlam K | |||
| Kavanaugh A | |||
| Geusens P | |||
| Guzzo C | |||
| Beutler A | |||
| Antoni C | |||
| Halter D | |||
| Dooley LT | |||
| Birbara C | |||
| P433 | issue | 8 | |
| P921 | main subject | psoriatic arthritis | Q511097 |
| P304 | page(s) | 2698-2707 | |
| P577 | publication date | 2007-08-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2 | |
| P478 | volume | 56 |
| Q36353577 | Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions |
| Q21093257 | Advances in rheumatology: new targeted therapeutics |
| Q47734526 | Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions |
| Q37590576 | Anti-IL17A in Axial Spondyloarthritis-Where Are We At? |
| Q36479450 | Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis |
| Q100465143 | Applying precision medicine to unmet clinical needs in psoriatic disease |
| Q89514351 | Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research |
| Q53706780 | Association of IL1Β (-511 A/C) and IL6 (-174 G > C) polymorphisms with higher disease activity and clinical pattern of psoriatic arthritis. |
| Q34153144 | Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion |
| Q84892267 | Drug therapy of inflammatory arthritis |
| Q91590639 | Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients |
| Q26851274 | Effects of anti-tumor necrosis factor α agents on bone |
| Q37979273 | Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal |
| Q37786627 | Golimumab: a new anti-TNF-α agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis |
| Q37116853 | Infliximab (Remicade) in the treatment of psoriatic arthritis |
| Q34176748 | Infliximab treatment in two Chinese patients with psoriatic arthritis |
| Q35070446 | Infliximab: 12 years of experience |
| Q38004958 | Is psoriatic arthritis a result of abnormalities in acquired or innate immunity? |
| Q37358124 | Long-term use of adalimumab in the treatment of rheumatic diseases. |
| Q34916347 | MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage |
| Q37930978 | Management of psoriatic arthritis from the view of the dermatologist |
| Q39367830 | Orthopaedic interventions in patients with psoriatic arthritis: a descriptive report from the SPAR cohort. |
| Q90394986 | Preliminary validation of the Simplified Psoriatic Arthritis Radiographic Score (SPARS) |
| Q22305856 | Profile of certolizumab and its potential in the treatment of psoriatic arthritis |
| Q37480069 | Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis |
| Q37051500 | Psoriatic arthritis: current topics |
| Q24813979 | Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment |
| Q37758453 | Psoriatic arthritis: pharmacotherapy update |
| Q40074154 | Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry |
| Q42534690 | Relationship between inflammation, bone destruction, and osteoproliferation in the HLA-B27/human β2 -microglobulin-transgenic rat model of spondylarthritis |
| Q92798584 | Remicade® (infliximab): 20 years of contributions to science and medicine |
| Q30399745 | Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders |
| Q34027596 | Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. |
| Q64885827 | Simultaneous quantification of bone erosions and enthesiophytes in the joints of patients with psoriasis or psoriatic arthritis - effects of age and disease duration. |
| Q34613907 | Spondyloarthritides: evolving therapies |
| Q37891477 | Spondyloarthritis |
| Q37882064 | Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future |
| Q26764867 | Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies |
| Q34108110 | The emerging field of osteoimmunology |
| Q37313490 | The treatment of psoriatic arthritis and inflammatory spondylitis |
| Q38204241 | Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety |
| Q38685543 | Tumor necrosis factor inhibitors in psoriatic arthritis. |
| Q30760660 | Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla |
| Q43705459 | What are the risks of not intensively treating a chronic inflammatory disease? |
| Q92737085 | What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials |
| Q84514358 | [Development of morbidity and mortality in patients with spondyloarthritis] |
Search more.